Welcome to another Pinktober!

October is known as the worldwide awareness month of breast cancer. Previously, we have talked about how early detection and personalized cancer treatment plans are key factors in breast cancer control. The purpose of this year’s message is to focus on what can be done before? We’ll talk about some preventive measures which individuals can follow to take care of their well-being. 

Diversity Series: Serena & Loïc

HEMEX is pleased to introduce you to the new talented minds and charismatic personalities on the team! Are you curious? Then keep reading, because today you will learn more about our office manager and executive assistant Serena and our junior sales associate Loïc.

Announcing an exciting, unique & customer-focused collaboration

We’re delighted to announce a new collaboration between HEMEX and The Bioinformatics CRO which will provide an even more complete CRO service for our start-ups! Find out how this collaboration can support you throughout your Clinical Development phase.

How can we improve communication of clinical study information and make the Informed Consent process more patient-friendly ?

Complicated words and sentences may be misunderstood and are very often unfamiliar to the patients. This led us to discuss how we could find the optimal solution for all parties involved in a clinical study: the patient, physician, and sponsor/CRO.

Comms&Media: a new service for start-up companies powered by Benz Advisory, mediacrewgroup, and HEMEX

Benz Advisory, mediacrewgroup, and HEMEX join forces to support early-stage companies with strategic communications through a new service called Comms&Media. Targeted at early-stage businesses from all industries, it offers a unique, holistic approach to help companies develop and implement effective external and internal communications.

How To Bake A “Delicious” Pitch For Investors

Every Start-up knows the importance of a great pitch. Today we want to give you some advice on how to find out the essential ingredients to bake a delicious pitch which investors will enjoy every single bite. More importantly, leave them craving for more!

Resistell Announces Start Of Performance Evaluation Study

Resistell has started the Performance Evaluation Study (PES) of its groundbreaking nanomotion technology at Lausanne University Hospital. At HEMEX, are very happy to be part of this project, as we will be monitoring the clinical trial over the next 12 months.

Major Milestone For Our Portfolio Company Inura Medical, Who Closes Their Pre-series A Financing Round

Inura Medical’s mission is to improve women’s health through the development of an urethral ovulum for the treatment of patients suffering from urinary bladder diseases. Their first pharmaceutical product is addressing an unmet medical need in overactive bladder (OAB). 

Our portfolio company HexagonFab secures CHF 2.5m seed funding to speed discovery and production of the next-gen of biopharmaceuticals!

HexagonFab, a spin-out from the University of Cambridge, has developed a novel approach for drug discovery and production process monitoring called the Bolt. This innovative device is an analytical lab instrument that provides convenient and affordable access to molecular binding analytics.